# HGF

Source: https://onco.cc/targets/hgf/  
OnCo record `hgf` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HGF (Hepatocyte growth factor) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Gastric & gastro-oesophageal junction cancer, Skin cancer and 5 more.

## Summary

Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerisation. Activates MAPK signalling following TMPRSS13 cleavage and activation.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming MET Tyrosine Kinase Inhibitor SGX523. Open Targets scores its association with cancer at 0.78 (direct and indirect evidence; datatypes clinical 0.65, affected pathway 0.73, literature 1.00, genetic association 0.50, somatic mutation 0.83). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Small Cell Lung Cancer. In OnCo, 1 product record names it (Ficlatuzumab).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: hepatocyte growth factor; Hepatocyte growth factor; F-TCF; DFNB39
- Tags: cancer-genes-wave
- Symbol: HGF
- Class: oncogene
- Biology: Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerisation. Activates MAPK signalling following TMPRSS13 cleavage and activation. Locus 7q21.11 (HGNC).
- Where found: Lung cancer: Open Targets association 0.62 with lung cancer (MONDO_0008903); Gastric & gastro-oesophageal junction cancer: Open Targets association 0.59 with gastric cancer (MONDO_0001056); Skin cancer: Open Targets association 0.55 with skin cancer (MONDO_0002898); Ovarian cancer: Open Targets association 0.51 with ovarian cancer (MONDO_0008170); Glioma & glioblastoma: CIViC evidence names this disease; Small-cell lung cancer: IntOGen driver in 1 cohort (SCLC)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.65; IntOGen calls it an activating (Act) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:4893: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4893
- UniProt P14210: https://www.uniprot.org/uniprotkb/P14210/entry
- NCBI Gene 3082: https://www.ncbi.nlm.nih.gov/gene/3082
- Ensembl ENSG00000019991: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000019991

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Ficlatuzumab](https://onco.cc/drugs/ficlatuzumab/)
- pathways: [Invasion: proteases, adhesion & the invasive front](https://onco.cc/pathways/invasion-ecm-degradation/), [Proteoglycans in cancer](https://onco.cc/pathways/proteoglycans-in-cancer/), [Receptor tyrosine kinase activation](https://onco.cc/pathways/rtk-activation/), [Renal cell carcinoma (KEGG map)](https://onco.cc/pathways/renal-cell-carcinoma-signalling/)

---
JSON: https://onco.cc/api/v1/entities/hgf.json